A Phase 1/2 Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR402663 in Participants With Neovascular Age-related Macular Degeneration
Latest Information Update: 09 Apr 2025
At a glance
- Drugs SAR 402663 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Sanofi
Most Recent Events
- 04 Apr 2025 Planned End Date changed from 15 May 2031 to 30 Jun 2031.
- 27 Dec 2024 Status changed from not yet recruiting to recruiting.
- 05 Nov 2024 New trial record